Search Bar & Filters
Found 24 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.
Actively Recruiting
This research evaluates the safety and effectiveness of berobenatide in adults who are overweight or have obesity and have already lost weight while using semaglutide or tirzepatide. The study specifically excludes people with diabetes and aims to understand how well berobenatide helps maintain weight loss. It is a phase 3 randomized trial sponsored by Pfizer. Participants will be randomly assigned to receive either semaglutide or tirzepatide by subcutaneous injection as active comparators, or berobenatide by subcutaneous injection as the experimental treatment. The study compares continuing weekly injections of semaglutide or tirzepatide with switching to a monthly injection of berobenatide. Treatment duration and dosing schedules are designed to assess weight maintenance over approximately 11 months. During the study, participants will be monitored for changes in body weight from baseline to 32 weeks, including percent change and overall weight change. Safety will be closely observed through reports of treatment emergent adverse events, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. Laboratory tests will also be conducted to check for any abnormalities. Total participation lasts about 11 months to capture these outcomes fully.
Actively Recruiting
Researchers are evaluating the effectiveness of combination antibiotic therapy compared to single antibiotic therapy for adults hospitalized with Staphylococcus aureus bloodstream infections. This study focuses on patients identified as high-risk early in their infection and aims to determine if combination therapy improves outcomes compared to monotherapy. Both methicillin-sensitive and methicillin-resistant bacterial infections are included. The trial is a randomized, crossover Phase 4 study conducted in hospitals. Participants with methicillin-sensitive Staphylococcus aureus bacteremia MSSAB will receive either a single intravenous beta-lactam antibiotic cefazolin or nafcillin or combination therapy including that beta-lactam plus ertapenem. Those with methicillin-resistant Staphylococcus aureus bacteremia MRSAB will be treated with either monotherapy of vancomycin or daptomycin or combination therapy with daptomycin plus ceftaroline. Treatment assignments alternate monthly by hospital. Low-risk patients receive usual care without randomization. During the study, participants will be monitored from enrollment through 30 and 90 days for various outcomes including a desirability of outcome ranking, hospital-free days alive, mortality rates, bacteremia-free days, hospital length of stay, direct hospital costs, antibiotic costs, antibiotic-associated adverse events, and Clostridioides difficile infections. Data from all hospitalized patients with SAB at participating hospitals will be analyzed. The study is expected to complete in January 2029.
Actively Recruiting
Researchers are studying the long-term effects of aleniglipron, taken once daily, in adults with obesity or overweight who also have weight-related health problems. This Phase 3 global, randomized, placebo-controlled, and double-blind trial aims to evaluate how well aleniglipron works, how safe it is, and how well patients tolerate it over at least 76 weeks. The study also compares aleniglipron with placebo in terms of body weight changes, blood pressure, lipid levels, and patient-reported outcomes. Participants will be randomly assigned to receive one of three doses of aleniglipron or a placebo, all taken orally once daily. Along with the medication, all participants will follow a reduced-calorie diet and increase physical activity. The treatment phase lasts at least 76 weeks, during which effects on weight and other health measures will be assessed. During the study, participants will undergo assessments of body weight, waist size, blood pressure, cholesterol, blood sugar, and quality of life measures from the start through week 76. Researchers will monitor safety and tolerability throughout the treatment period. This long-term study will help understand the impact of aleniglipron on weight management and related health factors over more than a year of treatment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
Researchers are evaluating two different lymph node assessment methods during minimally invasive hysterectomy for patients with stage I endometrial cancer confined to the uterus. This phase III trial compares sentinel lymph node SLN mapping, which uses a special dye and camera to identify lymph nodes, with the standard lymph node dissection that removes nodes around the uterus. The goal is to assess which method better reduces the risk of swelling in the legs, also known as lymphedema, and to understand potential long-term impacts on limb function and cancer outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive an injection of indocyanine green ICG dye for SLN mapping and excision if mapping is incomplete, additional lymph nodes may be removed on that side. In the second group, patients also receive ICG dye and undergo SLN mapping but then have additional lymph nodes removed as per standard care. Both groups undergo minimally invasive hysterectomy, imaging as needed, and optional blood sample collection throughout the study. After surgery, participants are followed regularly with visits every three months for one year, and then at 18 and 24 months. Researchers will collect patient-reported symptoms using questionnaires, measure changes in leg circumference, track SLN detection and cancer spread, and monitor complications. The main outcome is the occurrence of leg dysfunction reported by patients from 18 to 39 months after surgery. The study also examines treatment decisions, safety, and cost-effectiveness of the lymph node assessment strategies.
1-10 of 24
1